Tag Archives: M&A

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the […]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments

Pfizer Adds FoldRx to its Specialty Care Unit

Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money. Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become […]
Posted in Deals, Strategy | Also tagged , | Leave a comment

Genzyme Snubs Sanofi Offer

Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it. “Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your […]
Posted in Deals | Also tagged , | 1 Comment

M&A Round-up • 3/25/2009

The latest round of merger and acquisition activities courtesy of our friends at Pharm Exec Europe: • Just days after its purchase of Genentech, Roche has made another acquisition, albeit a much smaller one, of the German firm Innovatis. Roche will pay EUR 15 million for the cell analytics company. • Oxford Gene Technology (OGT) […]
Posted in Deals | Also tagged , , , , , , , , , | Leave a comment

Roche and Genentech Seal the Deal
for $46.8 Billion

After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. Roche plans to keep the Genentech site […]
Posted in Biotech | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta